Financings
Rize Oncology Announces Warrant Incentive Program
RIZE · Price
Executive Summary
- Rize Oncology has implemented a warrant incentive program to encourage the early exercise of existing common share purchase warrants.
- Holders who exercise their warrants by May 13, 2026, will benefit from a significantly discounted exercise price and receive additional "Incentive Warrants."
- Proceeds generated from the early exercise of these warrants will be used for general working capital.
Key Details
- Eligible Warrants:
- 25,000,000 common share purchase warrants issued January 6, 2025 ("January Warrants").
- 5,000,000 common share purchase warrants issued October 30, 2025 ("October Warrants").
- Original Exercise Prices:
- January Warrants: $0.05/share.
- October Warrants: $0.30/share.
- Incentive Program Terms (for exercises on or before May 13, 2026):
- Discounted Exercise Price: Reduced to $0.02/share for both sets of warrants.
- Bonus Incentive: Holders receive one "Incentive Warrant" for no additional consideration for each warrant exercised.
- Incentive Warrant Terms:
- Exercise Price: $0.05/share.
- Expiry Date: December 31, 2028.
- Expected Issuance Date: On or about May 20, 2026.
- Deadline and Reversion: Any warrants not exercised by 4:00 p.m. (Vancouver time) on May 13, 2026, will remain outstanding under their original terms and exercise prices.
- Hold Periods:
- Common shares issued via the exercise of existing warrants are not subject to a hold period.
- Incentive Warrants and any shares issued upon their exercise are subject to a four-month hold period from the date of distribution.
- Related Party Transaction: The company noted that certain insiders are expected to participate; Rize Oncology is relying on exemptions from MI 61-101 (formal valuation and shareholder approval) based on financial hardship and the fact that its securities are not listed on a specified market.